Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial.
BACKGROUND
A large proportion of patients with T2DM in China do not meet accepted HbA1c targets despite the availability of guidelines that describe a treatment pathway for achieving glycemic control. The aim of this study is to identify the fasting plasma glucose (FPG) target that will provide the highest control rate of HbA1c <7 % in Chinese patients with T2DM treated with an insulin glargine-based regimen as an adjunct to an established OAD regimen. This information will support improvements in diabetes care management in China.


METHODS
Approximately 934 men and women aged ≥18 to ≤65 years with poorly controlled T2DM will be enrolled and randomized to one of three FPG target groups; ≤5.6 mmol/L, ≤6.1 mmol/L, or ≤7.0 mmol/L. They will be initiated on daily insulin glargine (Lantus®) in addition to their usual OAD regimen for 24 weeks. Patients will self-monitor fasting blood glucose (SM-FBG), and the study physician will titrate the basal insulin dose according to the SM-FBG results. In addition, HbA1c and safety will be recorded. We plan to statistically derive the optimal FPG target for an HbA1c of <7 %.


CONCLUSIONS
In China, treatment strategies that would achieve an optimum balance between glycemic control (as per HbA1c) and hypoglycemia are imperative to ensure improvements in the management of T2DM. Furthermore, elucidating the contribution of FPG to HbA1c in Chinese patients with T2DM and identifying a predictable relationship between FPG and HbA1c would be a valuable tool for patient self-management of diabetes.


BACKGROUND
NCT02545842 . Registered on 8 September 2015.
China-Japan Friendship Hospital, East Yinghuayuan Street, Hepingli, Beijing, 100029, People's Republic of China. ywying_1010@163.com.
Wenying
W
Yang
China-Japan Friendship Hospital, East Yinghuayuan Street, Hepingli, Beijing, 100029, People's Republic of China.
Zhaojun
Z
Yang
Jing'An Kerry Centre, 19F, Tower III, No.1228M, Yan'an Road, Shanghai, 200040, People's Republic of China.
Jing
J
Zhao
Jing'An Kerry Centre, 19F, Tower III, No.1228M, Yan'an Road, Shanghai, 200040, People's Republic of China.
Hai
H
Lu
Jing'An Kerry Centre, 19F, Tower III, No.1228M, Yan'an Road, Shanghai, 200040, People's Republic of China.
Tianhong
T
Luo
Fasting plasma glucose; Oral antidiabetic drugs; Self-monitor fasting blood glucose; Type 2 diabetes mellitus; glycated hemoglobin
Med Sci Monit. 2006 Jul;12(7):RA130-47
16810145
Diabetes Care. 2012 Apr;35(4):749-53
22323416
Curr Med Res Opin. 2012 Apr;28(4):533-41
22449098
Diabetes Ther. 2015 Jun;6(2):197-211
26088603
J Am Osteopath Assoc. 2013 Feb;113(2):152-62
23412677
J Diabetes. 2011 Sep;3(3):208-16
21631903
Diabetes Care. 2014 Jan;37 Suppl 1:S14-80
24357209
Pharmacoeconomics. 2015 Aug;33(8):811-31
25787932
J Diabetes Sci Technol. 2013 May 01;7(3):771-88
23759411
Lancet. 1998 Sep 12;352(9131):837-53
9742976
N Engl J Med. 2010 Mar 25;362(12):1090-101
20335585
Endocr Pract. 2011 Mar-Apr;17 Suppl 2:1-53
21474420
Diabetes Res Clin Pract. 2014 Apr;104(1):1-52
24508150
Lancet Diabetes Endocrinol. 2015 Aug;3(8):638-52
26051044
BMC Public Health. 2013 Jun 21;13:602
23800082
N Engl J Med. 2008 Oct 9;359(15):1577-89
18784090
Lancet Diabetes Endocrinol. 2014 Jun;2(6):474-80
24731674
Diabetes Care. 2015 Jan;38 Suppl:S8-S16
25537714
Diabetes Obes Metab. 2009 Jun;11(6):623-31
19515182
Curr Diab Rep. 2015 Jun;15(6):602
25944304
Endocr Pract. 2015 Apr;21 Suppl 1:1-87
25869408
Ann N Y Acad Sci. 2013 Apr;1281:64-91
23551121
Ann N Y Acad Sci. 2013 Apr;1281:51-63
23317344